JP5969015B2 - Ｔｒｐｖ４拮抗薬 - Google Patents

Ｔｒｐｖ４拮抗薬 Download PDF

Info

Publication number
JP5969015B2
JP5969015B2 JP2014516015A JP2014516015A JP5969015B2 JP 5969015 B2 JP5969015 B2 JP 5969015B2 JP 2014516015 A JP2014516015 A JP 2014516015A JP 2014516015 A JP2014516015 A JP 2014516015A JP 5969015 B2 JP5969015 B2 JP 5969015B2
Authority
JP
Japan
Prior art keywords
methyl
azaspiro
oxa
alkyl
benzo
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
JP2014516015A
Other languages
English (en)
Japanese (ja)
Other versions
JP2014520118A5 (enExample
JP2014520118A (ja
Inventor
カール、ブルックス
ムイ、チュン
クリスタ、ビー．グッドマン
マーリス、ハモンド
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
GlaxoSmithKline Intellectual Property No 2 Ltd
Original Assignee
GlaxoSmithKline Intellectual Property No 2 Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by GlaxoSmithKline Intellectual Property No 2 Ltd filed Critical GlaxoSmithKline Intellectual Property No 2 Ltd
Publication of JP2014520118A publication Critical patent/JP2014520118A/ja
Publication of JP2014520118A5 publication Critical patent/JP2014520118A5/ja
Application granted granted Critical
Publication of JP5969015B2 publication Critical patent/JP5969015B2/ja
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/10—Drugs for disorders of the urinary system of the bladder
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/08—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing alicyclic rings

Landscapes

  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Medicinal Chemistry (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Biomedical Technology (AREA)
  • Urology & Nephrology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Psychology (AREA)
  • Vascular Medicine (AREA)
  • Hospice & Palliative Care (AREA)
  • Pain & Pain Management (AREA)
  • Immunology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Rheumatology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
JP2014516015A 2011-06-17 2012-06-15 Ｔｒｐｖ４拮抗薬 Expired - Fee Related JP5969015B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201161498099P 2011-06-17 2011-06-17
US61/498,099 2011-06-17
PCT/US2012/042603 WO2012174340A1 (en) 2011-06-17 2012-06-15 Trpv4 antagonists

Publications (3)

Publication Number Publication Date
JP2014520118A JP2014520118A (ja) 2014-08-21
JP2014520118A5 JP2014520118A5 (enExample) 2015-07-16
JP5969015B2 true JP5969015B2 (ja) 2016-08-10

Family

ID=47357482

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2014516015A Expired - Fee Related JP5969015B2 (ja) 2011-06-17 2012-06-15 Ｔｒｐｖ４拮抗薬

Country Status (5)

Country Link
US (1) US8927585B2 (enExample)
EP (1) EP2720697B1 (enExample)
JP (1) JP5969015B2 (enExample)
ES (1) ES2595606T3 (enExample)
WO (1) WO2012174340A1 (enExample)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JO3154B1 (ar) * 2011-06-17 2017-09-20 Glaxosmithkline Llc عوامل مضادة لـ trpv4
US9487507B2 (en) 2011-06-17 2016-11-08 Glaxosmithkline Intellectual Property (No. 2) Limited TRPV4 antagonists
US9499533B2 (en) 2012-03-27 2016-11-22 Shionogi & Co., Ltd. Aromatic 5-membered heterocyclic derivative having TRPV4-Inhibiting activity
WO2015046193A1 (ja) 2013-09-25 2015-04-02 塩野義製薬株式会社 Ｔｒｐｖ４阻害活性を有する芳香族複素環式アミン誘導体
ES2813108T3 (es) * 2016-05-19 2021-03-22 Glaxosmithkline Ip No 2 Ltd Antagonista de TRPV4
US10968209B2 (en) 2016-05-19 2021-04-06 Glaxosmithkline Intellectual Property (No.2) Limited TRPV4 antagonist
WO2018185701A1 (en) * 2017-04-06 2018-10-11 Glaxosmithkline Intellectual Property (No.2) Limited Trpv4 antagonists as antitussive agents
JP7692219B2 (ja) 2020-04-30 2025-06-13 ラクオリア創薬株式会社 Ｔｒｐｖ４拮抗薬としてのピリミジン－４（３ｈ）－オン誘導体
EP4183415A4 (en) 2020-07-16 2024-07-17 RaQualia Pharma Inc. Trpv4 inhibitor as therapeutic drug for eye disease
EP4551572A1 (en) 2022-07-08 2025-05-14 Actio Biosciences, Inc. Therapeutic compounds and methods

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE482945T1 (de) 1998-05-26 2010-10-15 Chugai Pharmaceutical Co Ltd Heterozyklische indolderivate und mono- oder diazaindol-derivate
EP1187610A2 (en) 1999-05-12 2002-03-20 Neurosearch A/S Use of ion channel modulating agents
CA2531619A1 (en) * 2003-07-16 2005-01-27 Neurogen Corporation Biaryl piperazinyl-pyridine analogues
TW200819457A (en) * 2006-08-30 2008-05-01 Actelion Pharmaceuticals Ltd Spiro antibiotic derivatives
US20090042897A1 (en) 2007-02-01 2009-02-12 Glaxo Group Limited Chemical Compounds
GB0707934D0 (en) 2007-04-24 2007-05-30 Glaxo Group Ltd Chemical compounds
MX2010001486A (es) * 2007-08-09 2010-03-01 Abbott Lab Derivados de tetrahidropiridin carboxamida como antagonistas de trpvl.
TW200944520A (en) * 2008-01-29 2009-11-01 Glaxo Group Ltd Spiro compounds as NPY Y5 receptor antagonists
US8450484B2 (en) * 2008-07-25 2013-05-28 GlaxoSmithKline, LLC TRPV4 antagonists
JP2012006837A (ja) * 2008-09-30 2012-01-12 Mochida Pharmaceut Co Ltd ２−インドールアクリルアミド類縁体
JO3154B1 (ar) 2011-06-17 2017-09-20 Glaxosmithkline Llc عوامل مضادة لـ trpv4
US9487507B2 (en) * 2011-06-17 2016-11-08 Glaxosmithkline Intellectual Property (No. 2) Limited TRPV4 antagonists

Also Published As

Publication number Publication date
ES2595606T3 (es) 2017-01-02
US20140135369A1 (en) 2014-05-15
WO2012174340A1 (en) 2012-12-20
EP2720697B1 (en) 2016-07-20
JP2014520118A (ja) 2014-08-21
EP2720697A1 (en) 2014-04-23
US8927585B2 (en) 2015-01-06
EP2720697A4 (en) 2014-12-31

Similar Documents

Publication Publication Date Title
JP5969016B2 (ja) Ｔｒｐｖ４拮抗薬
JP2014520118A (ja) Ｔｒｐｖ４拮抗薬
JP5969017B2 (ja) Ｔｒｐｖ４拮抗薬
EP3615534B1 (en) Fused pentacyclic imidazole derivatives as modulators of tnf activity
JP5607046B2 (ja) Ｔｒｐｖ４拮抗薬
TWI543974B (zh) 苯基－３－氮雜－雙環［３．１．０］己－３－基－甲酮及其作為藥物之用途
CA3211820A1 (en) Isoquinolone compound and use thereof
JP7481435B2 (ja) Ｃｒａｃ阻害剤としての２ｈ－ベンゾピラン誘導体
CA3121199A1 (en) Diarylhydantoin compounds and methods of use thereof
EP3886854A1 (en) Pyrrole and pyrazole compounds and methods of use thereof
JP6428763B2 (ja) アミド化合物
JP6885962B2 (ja) １，４−ジカルボニル−ピペリジル誘導体
JP2017518378A (ja) 小分子ｌｆａ−１阻害薬
JP2013522372A (ja) Ｔｒｐｖ４拮抗薬
JP2022532416A (ja) Ｐａｒｒ阻害剤としてのキナゾリン―２．４―ジオン誘導体
JP2025539352A (ja) オレキシン受容体２の置換大環状アミン調節因子
HK40024466A (en) Fused pentacyclic imidazole derivatives as modulators of tnf activity
HK40024466B (en) Fused pentacyclic imidazole derivatives as modulators of tnf activity
NZ618221B2 (en) Trpv4 antagonists
HK1195068B (en) Trpv4 antagonists
CN101087765A (zh) 稠合吡唑衍生物和其在治疗代谢相关病症的方法中的用途

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20150526

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20150526

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20151222

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20151224

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20160322

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20160607

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20160706

R150 Certificate of patent or registration of utility model

Ref document number: 5969015

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

LAPS Cancellation because of no payment of annual fees